BACKGROUND: p53 mutations are frequently observed in colorectal carcinomas but they have also been found in colorectal adenomas, although considerably less frequently. AIMS: To explore p53 mutations in benign tumours, we have screened 70 colorectal adenomas for allelic loss at, and point mutations in, TP53 by analysis of selected microdissected cell populations. RESULTS: Sixteen (22.8%) adenomas were found to have allelic loss, of which 11 (15.7%) had p53 mutations. In adenomas with mild, moderate, or severe dysplasia, mutation or allelic loss occurred in 4.8%, 16.7%, and 52.6%, respectively (p<0.001). Seven different mutations were found, all missense changes or inframe deletions: one (Thr150Arg) has not been found before while three (Gln144His, Gly245Arg, and Glu285Gln) have not been described previously in colorectal tumours. The other three mutations (Arg175Gly, DeltaPro190, and Gly245Ser) have been found in colorectal carcinomas, the last commonly. Adenomas harboured a spectrum of p53 mutations which was significantly different from cancers as regards the position in the gene and a higher frequency of G-->C/C-->G changes. CONCLUSIONS: Combining our data on adenomas with data already published and in comparison with the spectrum of mutations in colorectal carcinomas, it is suggested that some p53 mutations have a weaker effect than others and are therefore more likely to be found in adenomas which have not progressed to carcinomas.
BACKGROUND:p53 mutations are frequently observed in colorectal carcinomas but they have also been found in colorectal adenomas, although considerably less frequently. AIMS: To explore p53 mutations in benign tumours, we have screened 70 colorectal adenomas for allelic loss at, and point mutations in, TP53 by analysis of selected microdissected cell populations. RESULTS: Sixteen (22.8%) adenomas were found to have allelic loss, of which 11 (15.7%) had p53 mutations. In adenomas with mild, moderate, or severe dysplasia, mutation or allelic loss occurred in 4.8%, 16.7%, and 52.6%, respectively (p<0.001). Seven different mutations were found, all missense changes or inframe deletions: one (Thr150Arg) has not been found before while three (Gln144His, Gly245Arg, and Glu285Gln) have not been described previously in colorectal tumours. The other three mutations (Arg175Gly, DeltaPro190, and Gly245Ser) have been found in colorectal carcinomas, the last commonly. Adenomas harboured a spectrum of p53 mutations which was significantly different from cancers as regards the position in the gene and a higher frequency of G-->C/C-->G changes. CONCLUSIONS: Combining our data on adenomas with data already published and in comparison with the spectrum of mutations in colorectal carcinomas, it is suggested that some p53 mutations have a weaker effect than others and are therefore more likely to be found in adenomas which have not progressed to carcinomas.
Authors: L De Benedetti; L Varesco; N S Pellegata; L Losi; V Gismondi; L Casarino; S Sciallero; L Bonelli; R Biticchi; A Bafico Journal: Anticancer Res Date: 1993 May-Jun Impact factor: 2.480
Authors: R Kikuchi-Yanoshita; M Konishi; S Ito; M Seki; K Tanaka; Y Maeda; H Iino; M Fukayama; M Koike; T Mori Journal: Cancer Res Date: 1992-07-15 Impact factor: 12.701
Authors: Lina Welz; Nassim Kakavand; Xiang Hang; Georg Laue; Go Ito; Miguel Gomes Silva; Christina Plattner; Neha Mishra; Felicitas Tengen; Christoph Ogris; Moritz Jesinghaus; Felix Wottawa; Philipp Arnold; Leena Kaikkonen; Stefanie Stengel; Florian Tran; Saumya Das; Arthur Kaser; Zlatko Trajanoski; Richard Blumberg; Christoph Roecken; Dieter Saur; Markus Tschurtschenthaler; Stefan Schreiber; Philip Rosenstiel; Konrad Aden Journal: Gastroenterology Date: 2021-09-30 Impact factor: 22.682
Authors: Maria Tzouvala; Andreas C Lazaris; George V Papatheodoridis; Chariklia Kouvidou; Thomas G Papathomas; Nikos Kavantzas; Ioannis Elemenoglou; Demetrios G Karamanolis; Emmanouil Agapitos Journal: Dig Dis Sci Date: 2007-06-12 Impact factor: 3.199
Authors: Bálint Péterfia; Alexandra Kalmár; Árpád V Patai; István Csabai; András Bodor; Tamás Micsik; Barnabás Wichmann; Krisztina Egedi; Péter Hollósi; Ilona Kovalszky; Zsolt Tulassay; Béla Molnár Journal: J Cancer Date: 2017-01-12 Impact factor: 4.207
Authors: Jennifer K Pleiman; Amy A Irving; Zhishi Wang; Erik Toraason; Linda Clipson; William F Dove; Dustin A Deming; Michael A Newton Journal: PLoS Genet Date: 2018-09-06 Impact factor: 5.917
Authors: Ann-Marie Baker; William Cross; Kit Curtius; Ibrahim Al Bakir; Chang-Ho Ryan Choi; Hayley Louise Davis; Daniel Temko; Sujata Biswas; Pierre Martinez; Marc J Williams; James O Lindsay; Roger Feakins; Roser Vega; Stephen J Hayes; Ian P M Tomlinson; Stuart A C McDonald; Morgan Moorghen; Andrew Silver; James E East; Nicholas A Wright; Lai Mun Wang; Manuel Rodriguez-Justo; Marnix Jansen; Ailsa L Hart; Simon J Leedham; Trevor A Graham Journal: Gut Date: 2018-07-10 Impact factor: 23.059